or Try an Advanced Search...

    Technical Analysis for TCRX - TScan Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 5.93 1.37% 0.08
    TCRX closed up 1.37 percent on Monday, July 1, 2024, on 3.59 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical TCRX trend table...
    Date Alert Name Type % Chg
    Hammer Candlestick Bullish 0.00%
    Lizard Bullish Bullish Day Trade Setup 0.00%
    Volume Surge Other 0.00%
    Doji - Bullish? Reversal 0.00%
    Wide Bands Range Expansion 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 200 DMA Bearish 1.37%
    New Downtrend Bearish 1.37%
    Volume Surge Other 1.37%
    Older End-of-Day Signals for TCRX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    2x Volume Pace about 8 hours ago
    Fell Below Lower Bollinger Band about 8 hours ago
    Down 10% about 8 hours ago
    60 Minute Opening Range Breakdown about 8 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    TCRX Chart by TradingView
    Basic chart:

    Profile

    TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer

    Is TCRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 24 TScan Therapeutics Decline Means Insider Profits Down To US$54k
    Jun 24 Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
    Jun 14 TScan Therapeutics Announces Updates to its Board of Directors
    May 30 TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
    May 29 TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
    May 14 TScan Therapeutics First Quarter 2024 Earnings: Misses Expectations
    May 13 TScan Therapeutics GAAP EPS of -$0.32, revenue of $0.56M
    May 13 TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
    May 13 Key Takeaways From TScan Therapeutics Analyst Ratings
    May 13 TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    See more TCRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.69
    52 Week Low 1.94
    Average Volume 370,436
    200-Day Moving Average 6.03
    50-Day Moving Average 7.99
    20-Day Moving Average 7.57
    10-Day Moving Average 6.51
    Average True Range 0.70
    RSI (14) 31.97
    ADX 28.34
    +DI 9.03
    -DI 30.16
    Chandelier Exit (Long, 3 ATRs) 7.18
    Chandelier Exit (Short, 3 ATRs) 7.29
    Upper Bollinger Bands 9.83
    Lower Bollinger Band 5.31
    Percent B (%b) 0.14
    BandWidth 59.74
    MACD Line -0.65
    MACD Signal Line -0.43
    MACD Histogram -0.2238
    Fundamentals Value
    Market Cap 258.24 Million
    Num Shares 43.5 Million
    EPS -2.02
    Price-to-Earnings (P/E) Ratio -2.94
    Price-to-Sales 16.41
    Price-to-Book 1.70
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.06
    Resistance 3 (R3) 6.93 6.43 6.87
    Resistance 2 (R2) 6.43 6.14 6.49 6.80
    Resistance 1 (R1) 6.18 5.97 6.31 6.31 6.74
    Pivot Point 5.68 5.68 5.74 5.74 5.68
    Support 1 (S1) 5.43 5.39 5.56 5.56 5.12
    Support 2 (S2) 4.93 5.22 4.99 5.06
    Support 3 (S3) 4.68 4.93 4.99
    Support 4 (S4) 4.81